An in vitro rapid qualitative test that detects influenza type A and type B antigens directly from nasal swab, nasopharyngeal swab and nasal aspirate/wash specimens.
Features and Benefits
Features and Benefits
- Meets the new FDA reclassification performance criteria
- CLIA WAIVED for swab specimens
- Includes Positive and Negative control swabs
- Innovative flip design with on board sample extraction
- Differentiates between Influenza A and B
- Pre-measured developer solution capsule for increased accuracy and ease of use
- Flocked nasal swabs for improved patient comfort and superior specimen collection
Simple Test Procedure
Sample Results
Proven Clinical Performance
Sample Results
Proven Clinical Performance
